Zila to Introduce Ester-C(R) Advanced Vitamin C into Japan; Asahi Godo Signs Distributor Agreement
November 17 2005 - 12:10PM
Business Wire
Zila, Inc., (NASDAQ:ZILA), announced today that its wholly owned
subsidiary, Zila Nutraceuticals, Inc., has signed an agreement with
Asahi Godo to distribute its Ester-C(R) advanced vitamin C
ingredient in Japan. As part of this agreement, Zila Nutraceuticals
and Asahi Godo will work together to attain Japanese regulatory
approval in order to allow the sale of Ester-C(R), considered a
food additive in Japan, in vitamin and dietary supplement products
as well as foods and beverages. According to the Global Nutrition
Group, a Tokyo-based research consulting firm, sales in the
Japanese nutrition market reached nearly 30 billion US dollars in
2004, making it the world's second largest market behind the United
States for nutrition products. "The introduction of Ester-C(R) into
the second largest nutritional supplement market in the world
represents a major milestone in the execution of Zila
Nutraceuticals' aggressive international plan," said Douglas D.
Burkett, Ph.D., Chairman, Chief Executive Officer and President of
Zila, Inc. "We are very excited about this new partnership and are
fully committed to bringing the benefits of Ester-C(R) to the
people of Japan as well as to consumers throughout the world."
About Asahi Godo Founded in 1966, Asahi Godo is headquartered in
Kyoto with branch offices in Tokyo and Shizouka, Japan. The company
provides health supplements and packaging services to major
Japanese companies within the nutritional, cosmetic, and
pharmaceutical industries. "We look forward to our partnership with
Zila and feel very confident that we can make Ester-C(R) the
number-one branded ingredient in the Japanese supplement market,"
said Tadato Shiono, General Manager of Asahi Godo. About Ester-C
Ester-C(R) calcium ascorbate is an advanced form of vitamin C.
Unlike regular vitamin C, Ester-C(R) is non-acidic, so it's gentle
on the stomach. Ester-C(R) is a readily absorbed form of vitamin C
that helps support immune health, heart health, joint health and
vision. For more information about Ester-C(R), visit
www.ester-c.com. Ester-C(R) is the registered trademark of Zila
Nutraceuticals, Inc. Information and statements regarding dietary
supplements have not been evaluated by the Food and Drug
Administration and are not intended to diagnose, treat, cure, or
prevent any disease. About Zila Zila, Inc., headquartered in
Phoenix, is an innovator in preventative healthcare technologies
and products, focusing on enhanced body defense and the detection
of pre-disease states. Zila has three business units: -- Zila
Biotechnology, a research, development and licensing business
specializing in pre-cancer/cancer detection through its patented
Zila Tolonium Chloride and OraTest(R) technologies. -- Zila
Pharmaceuticals, marketer of products to promote oral health and
prevent oral disease, including ViziLite(R) Plus oral lesion
identification kits and Peridex(R) prescription periodontal rinse.
-- Zila Nutraceuticals, manufacturer and marketer of Ester-C(R) and
Ester-E(TM) branded, highly effective forms of Advanced Protection
vitamins C and E. For more information about Zila, visit
www.zila.com. This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
These forward-looking statements are based largely on Zila's
expectations or forecasts of future events, can be affected by
inaccurate assumptions and are subject to various business risks
and known and unknown uncertainties, a number of which are beyond
the Company's control. Therefore, actual results could differ
materially from the forward-looking statements contained herein. A
wide variety of factors could cause or contribute to such
differences and could adversely impact revenues, margins,
profitability, cash flows and capital needs, the ability of the
Company to maintain required cash flows and cash availability to
implement its business plan and appreciation in the market value of
Zila's common stock. Such factors include, but are not limited to:
increased competition from current competitors and new market
entrants; the Company's ability to maintain, expand, or in certain
cases, regain distribution within new or existing channels of trade
for its products. There can be no assurance that the
forward-looking statements contained in this press release will, in
fact, transpire or prove to be accurate. For a more detailed
description of these and other cautionary factors that may affect
Zila's future results, please refer to Zila's Report on Form 10-K
for its fiscal year ended July 31, 2005, filed with the Securities
and Exchange Commission.
Zila (NASDAQ:ZILA)
Historical Stock Chart
From May 2024 to Jun 2024
Zila (NASDAQ:ZILA)
Historical Stock Chart
From Jun 2023 to Jun 2024